| |||||||
Type Mutant Stock; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Species laboratory mouse Generation N3 Donating Investigator David Baltimore, California Institute of Technology Appearance
white-bellied agouti
Related Genotype: Aw/?
black
Related Genotype: a/aDescription
Mice homozygous for the Relatm1Bal targeted mutation die at embryonic day 14 from hepatocyte apoptosis and failure of hematopoiesis
| Control | ||
|---|---|---|
| Wild-type from the colony | ||
| 101045 B6129SF2/J | (approximate) | |
| Considerations for Choosing Controls | ||
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
Relatm1Bal/Relatm1Bal
involves: 129S4/SvJae * C57BL/6J
- lethality-prenatal/perinatal
- lethality throughout fetal growth and development (MGI Ref ID J:28390)
- after E14 mice begin to die and none survive to birth
- liver/biliary system phenotype
- increased hepatocyte apoptosis (MGI Ref ID J:28390)
- liver degeneration is associated with increased apoptosis of liver cells
- liver degeneration (MGI Ref ID J:28390)
- E15 to E16, mice exhibit liver degeneration that specifically targets hepatocytes leaving hematopoietic precursors and red blood cells intact
- liver degeneration is associated with increased apoptosis of liver cells
- cardiovascular system phenotype
- internal hemorrhage (MGI Ref ID J:28390)
- at E16, surviving mice exhibit massive abdominal hemorrhage
Relatm1Bal/Relatm1Bal
B6;129S4-Relatm1Bal/J
- homeostasis/metabolism phenotype
- *normal* homeostasis/metabolism phenotype (MGI Ref ID J:91366)
- despite altered expression of Trp53, neurons exhibit normal camptothecin-induced neuronal death
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Relatm1Bal/Relatm1Bal
involves: 129S4/SvJae
- nervous system phenotype
- abnormal neuron physiology (MGI Ref ID J:119844)
- survival following treatment of sensory neurons with NGF is lower than for similarly treated wild-type neurons due to increased apoptosis
- however, sensory neurons exhibit normal survival response to BDNF
- abnormal trigeminal nerve morphology (MGI Ref ID J:119844)
- at E14, the number of neurons in the trigeminal ganglia is decrease compared to in wild-type mice
- increased neuron apoptosis (MGI Ref ID J:119844)
- apoptosis in the trigeminal ganglia of E14 mice is increased compared to in wild-type mice
- cellular phenotype
- abnormal cell death (MGI Ref ID J:28390)
- embryonic fibroblasts treated with mTNF-alpha exhibit decreased survival compared to similarly treated cells
- immune system phenotype
- *normal* immune system phenotype (MGI Ref ID J:113514)
- mice exhibit normal dendritic cell development and maturation
- decreased marginal zone B cell number (MGI Ref ID J:65246)
- when cells are used to reconstitute a Rag2 null mouse, the number of marginal zone B cells is reduced to one third of normal
- hematopoietic system phenotype
- decreased marginal zone B cell number (MGI Ref ID J:65246)
- when cells are used to reconstitute a Rag2 null mouse, the number of marginal zone B cells is reduced to one third of normal
Relatm1Bal/Relatm1Bal
B6.129S4-Relatm1Bal
- lethality-prenatal/perinatal
- lethality throughout fetal growth and development (MGI Ref ID J:111325)
- despite normal appearance up to E13, all mice are dead by E15
- liver/biliary system phenotype
- increased hepatocyte apoptosis (MGI Ref ID J:111325)
- most mice exhibit fetal liver cell apoptosis by E14.5
- cardiovascular system phenotype
- internal hemorrhage (MGI Ref ID J:111325)
- most mice exhibit abdominal hemorrhage by E14.5
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:Relatm1Bal related
Cancer Research
Oncogenes
Developmental Biology Research
Internal/Organ Defects (liver)
Internal/Organ Research
Liver Defects
| Allele Symbol | Relatm1Bal | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, David Baltimore | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | p65-; rela-; | ||
| Mutation Made By | David Baltimore, California Institute of Technology | ||
| Strain of Origin | 129S4/SvJae | ||
| ES Cell Line Name | J1 | ||
| ES Cell Line Strain | 129S4/SvJae | ||
| Gene Symbol and Name | Rela, v-rel reticuloendotheliosis viral oncogene homolog A (avian) | ||
| Chromosome | 19 | ||
| Gene Common Name(s) | MGC131774; NFKB3; NFkB; p65; p65 NF kappaB; | ||
| Molecular Note | The gene was disrupted using neomycin resistance cassette. The vector replaced sequences encoding most of exos 6, 8 and the entire exon 7. Protein was not detectable by Western analysis in embryonic fibroblast extracts from homozygous mutant animals. [MGI Ref ID J:28390] | ||
Genotyping Protocols
NEOTD (Generic Neo), STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
Beg AA; Sha WC; Bronson RT; Ghosh S; Baltimore D. 1995. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376(6536):167-70. [PubMed: 7603567] [MGI Ref ID J:28390]
Relatm1Bal relatedAlcamo E; Hacohen N; Schulte LC; Rennert PD; Hynes RO; Baltimore D. 2002. Requirement for the NF-kappaB family member RelA in the development of secondary lymphoid organs. J Exp Med 195(2):233-44. [PubMed: 11805150] [MGI Ref ID J:76222]
Alcamo E; Mizgerd JP; Horwitz BH; Bronson R; Beg AA; Scott M; Doerschuk CM; Hynes RO; Baltimore D. 2001. Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-kappa B in leukocyte recruitment. J Immunol 167(3):1592-600. [PubMed: 11466381] [MGI Ref ID J:84897]
Aleyasin H; Cregan SP; Iyirhiaro G; O'Hare MJ; Callaghan SM; Slack RS; Park DS. 2004. Nuclear factor-(kappa)B modulates the p53 response in neurons exposed to DNA damage. J Neurosci 24(12):2963-73. [PubMed: 15044535] [MGI Ref ID J:90221]
Beg AA; Baltimore D. 1996. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death [see comments] Science 274(5288):782-4. [PubMed: 8864118] [MGI Ref ID J:36492]
Boyle K; Azari MF; Cheema SS; Petratos S. 2005. TNFalpha mediates Schwann cell death by upregulating p75NTR expression without sustained activation of NFkappaB. Neurobiol Dis 20(2):412-27. [PubMed: 15905096] [MGI Ref ID J:124444]
Cariappa A; Liou HC; Horwitz BH; Pillai S. 2000. Nuclear factor kappaB is required for the development of marginal zone B lymphocytes J Exp Med 192(8):1175-82. [PubMed: 11034607] [MGI Ref ID J:65246]
Chen X; Ding WX; Ni HM; Gao W; Shi YH; Gambotto AA; Fan J; Beg AA; Yin XM. 2007. Bid-independent mitochondrial activation in tumor necrosis factor alpha-induced apoptosis and liver injury. Mol Cell Biol 27(2):541-53. [PubMed: 17101783] [MGI Ref ID J:117693]
Dadgostar H; Zarnegar B; Hoffmann A; Qin XF; Truong U; Rao G; Baltimore D; Cheng G. 2002. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci U S A 99(3):1497-502. [PubMed: 11830667] [MGI Ref ID J:126969]
Demarchi F; Bertoli C; Greer PA; Schneider C. 2005. Ceramide triggers an NF-kappaB-dependent survival pathway through calpain. Cell Death Differ 12(5):512-22. [PubMed: 15933726] [MGI Ref ID J:111869]
Erdman S; Fox JG; Dangler CA; Feldman D; Horwitz BH. 2001. Typhlocolitis in NF-kappa B-deficient mice. J Immunol 166(3):1443-7. [PubMed: 11160181] [MGI Ref ID J:67107]
Gadjeva M; Tomczak MF; Zhang M; Wang YY; Dull K; Rogers AB; Erdman SE; Fox JG; Carroll M; Horwitz BH. 2004. A role for NF-kappaB subunits p50 and p65 in the inhibition of lipopolysaccharide-induced shock. J Immunol 173(9):5786-93. [PubMed: 15494531] [MGI Ref ID J:93765]
Gadjeva M; Wang Y; Horwitz BH. 2007. NF-kappaB p50 and p65 subunits control intestinal homeostasis. Eur J Immunol 37(9):2509-17. [PubMed: 17705134] [MGI Ref ID J:124335]
Grossmann M; Metcalf D; Merryfull J; Beg A; Baltimore D; Gerondakis S. 1999. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci U S A 96(21):11848-53. [PubMed: 10518539] [MGI Ref ID J:111325]
Grumont R; Hochrein H; O'Keeffe M; Gugasyan R; White C; Caminschi I; Cook W; Gerondakis S. 2001. c-Rel Regulates Interleukin 12 p70 Expression in CD8(+) Dendritic Cells by Specifically Inducing p35 Gene Transcription. J Exp Med 194(8):1021-32. [PubMed: 11602633] [MGI Ref ID J:72212]
Grumont R; Lock P; Mollinari M; Shannon FM; Moore A; Gerondakis S. 2004. The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression. Immunity 21(1):19-30. [PubMed: 15345217] [MGI Ref ID J:93602]
Gugasyan R; Christou A; O'Reilly LA; Strasser A; Gerondakis S. 2006. Bcl-2 transgene expression fails to prevent fatal hepatocyte apoptosis induced by endogenous TNFalpha in mice lacking RelA. Cell Death Differ 13(7):1235-7. [PubMed: 16485035] [MGI Ref ID J:126292]
Gugasyan R; Voss A; Varigos G; Thomas T; Grumont RJ; Kaur P; Grigoriadis G; Gerondakis S. 2004. The transcription factors c-rel and RelA control epidermal development and homeostasis in embryonic and adult skin via distinct mechanisms. Mol Cell Biol 24(13):5733-45. [PubMed: 15199130] [MGI Ref ID J:91366]
Hamanoue M; Middleton G; Wyatt S; Jaffray E; Hay RT; Davies AM. 1999. p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol Cell Neurosci 14(1):28-40. [PubMed: 10433815] [MGI Ref ID J:119844]
Kaufmann T; Gugasyan R; Gerondakis S; Dixit VM; Strasser A. 2007. Loss of the BH3-only protein Bid does not rescue RelA-deficient embryos from TNF-R1-mediated fatal hepatocyte destruction. Cell Death Differ 14(3):637-9. [PubMed: 17096024] [MGI Ref ID J:132334]
Lee KG; Xu S; Wong ET; Tergaonkar V; Lam KP. 2008. Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells. J Biol Chem 283(17):11189-98. [PubMed: 18276597] [MGI Ref ID J:136576]
Liou HC; Hsia CY. 2003. Distinctions between c-Rel and other NF-kappaB proteins in immunity and disease. Bioessays 25(8):767-80. [PubMed: 12879447] [MGI Ref ID J:84673]
Meffert MK; Chang JM; Wiltgen BJ; Fanselow MS; Baltimore D. 2003. NF-kappaB functions in synaptic signaling and behavior. Nat Neurosci 6(10):1072-8. [PubMed: 12947408] [MGI Ref ID J:85743]
Ouaaz F; Arron J; Zheng Y; Choi Y; Beg AA. 2002. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 16(2):257-70. [PubMed: 11869686] [MGI Ref ID J:113514]
Rao S; Gerondakis S; Woltring D; Shannon MF. 2003. c-Rel is required for chromatin remodeling across the IL-2 gene promoter. J Immunol 170(7):3724-31. [PubMed: 12646638] [MGI Ref ID J:125445]
Rosenfeld ME; Prichard L; Shiojiri N; Fausto N. 2000. Prevention of hepatic apoptosis and embryonic lethality in RelA/TNFR-1 double knockout mice. Am J Pathol 156(3):997-1007. [PubMed: 10702415] [MGI Ref ID J:60742]
Tomczak MF; Erdman SE; Davidson A; Wang YY; Nambiar PR; Rogers AB; Rickman B; Luchetti D; Fox JG; Horwitz BH. 2006. Inhibition of Helicobacter hepaticus-induced colitis by IL-10 requires the p50/p105 subunit of NF-kappa B. J Immunol 177(10):7332-9. [PubMed: 17082652] [MGI Ref ID J:140612]
Vaira S; Alhawagri M; Anwisye I; Kitaura H; Faccio R; Novack DV. 2008. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 118(6):2088-97. [PubMed: 18464930] [MGI Ref ID J:137682]
Zarnegar B; He JQ; Oganesyan G; Hoffmann A; Baltimore D; Cheng G. 2004. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci U S A 101(21):8108-13. [PubMed: 15148378] [MGI Ref ID J:90663]
Zhang JY; Green CL; Tao S; Khavari PA. 2004. NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK. Genes Dev 18(1):17-22. [PubMed: 14724177] [MGI Ref ID J:119420]
Zhang JY; Tao S; Kimmel R; Khavari PA. 2005. CDK4 regulation by TNFR1 and JNK is required for NF-kappaB-mediated epidermal growth control. J Cell Biol 168(4):561-6. [PubMed: 15699216] [MGI Ref ID J:129435]
Colony Maintenance
Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $1900.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
| Pricing for International shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $2470.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
| Standard Supply | Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| Wild-type from the colony | ||
| 101045 B6129SF2/J | (approximate) | |
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.